Dr. Sarina Schwarz

  • Since 12/2023: Head of Unit (junior) Translational Cancer Epidemiology at Leibniz-Institute for Prevention Research and Epidemiology - BIPS
  • 08/2023: PhD degree, University of Bremen
  • Since 09/2018: Researcher at Leibniz-Institute for Prevention Research and Epidemiology - BIPS
  • 10/2015 - 09/2018: M.Sc. Epidemiology, University of Bremen
  • 01/2016-08/2018: Working Student at the research group for Evidence-Based Public Health, Institute for Public Health und Nursing Research (IPP) & Leibniz-Institute for Prevention Research and Epidemiology (BIPS GmbH) in Bremen, Germany
  • 10/2012-09/2015: B.A. Public Health, University of Bremen
  • 10/2014-1/2015: Internship at the Institute for Public Health and Nursing Sciences (IPP)

  • Early detection and prevention of cancer, main focus: Colorectal cancer screening by colonoscopy and fecal occult blood test (effectiveness, utilization and quality)
  • Secondary and claims data

    ORCID logo

    Selected BIPS-Publications

  • Articles with peer review

  • Reilev M, Jensen PB, Ranch LS, Egenberg A, Furu K, Gembert K, Hägg D, Haug U, Karlstad Ø, Reutfors J, Schäfer W, Schwarz S, Smits E, Holthuis E, Herings R, Trifirò G, Kirchmayer U, Cesare Rosa A, Belleudi V, Gini R, Støvring Henrik, Hallas J. Methodology of the brodalumab assessment of hazards: A multicentre observational safety (BRAHMS) study. BMJ Open. 2023;13:e066057.
    https://doi.org/10.1136/bmjopen-2022-066057
  • Schwarz S, Hornschuch M, Pox C, Haug U. Colorectal cancer after screening colonoscopy: 10-year incidence by site and detection rate at first repeat colonoscopy. Clinical and Translational Gastroenterology. 2023;14(1):e00535.
    https://doi.org/10.14309/ctg.0000000000000535
  • Schwarz S, Hornschuch M, Pox C, Haug U. Polyp detection rate and cumulative incidence of post-colonoscopy colorectal cancer in Germany. International Journal of Cancer. 2023;152(8):1547-1555.
    https://doi.org/10.1002/ijc.34375
  • Braitmaier M, Schwarz S, Kollhorst B, Senore C, Didelez V, Haug U. Screening colonoscopy similarly prevented distal and proximal colorectal cancer: A prospective study among 55-69-year-olds. Journal of Clinical Epidemiology. 2022;149:118-126.
    https://doi.org/10.1016/j.jclinepi.2022.05.024
  • Heinig M, Heinze F, Schwarz S, Haug U. Initial and ten-year treatment patterns among 11,000 breast cancer patients undergoing breast surgery - An analysis of German claims data. BMC Cancer. 2022;22:130.
    https://doi.org/10.1186/s12885-022-09240-w
  • Hornschuch M, Schwarz S, Haug U. 10-year prevalence of diagnostic and screening colonoscopy use in Germany: A claims data analysis. European Journal of Cancer Prevention. 2022;31(6):497-504.
    https://doi.org/10.1097/CEJ.0000000000000736
  • Heinig M, Schwarz S, Haug U. Self-selection for mammography screening according to use of hormone replacement therapy: A systematic literature review. Cancer Epidemiology. 2021;71(Part A):101812.
    https://doi.org/10.1016/j.canep.2020.101812
    https://repository.publisso.de/resource/frl:6425860
  • Schwarz S, Oppelt KA, Heinig M, Haug U. Potential of German claims data to characterize utilization of new cancer drugs: The example of crizotinib. Future Oncology. 2021;17(18):2305-2313.
    https://doi.org/10.2217/fon-2020-1052
    https://repository.publisso.de/resource/frl:6428548
  • Schwarz S, Schäfer W, Horenkamp-Sonntag D, Liebentraut J, Haug U. Follow-up of 3 million persons undergoing colonoscopy in Germany: Utilization of repeat colonoscopies and polypectomies within 10 years. Clinical and Translational Gastroenterology. 2021;12(1):e00279.
    https://doi.org/10.14309/ctg.0000000000000279
  • Articles without peer review

  • Rischke N, Schwarz S, Haug U. Anwendung von Immuncheckpointinhibitoren in der Therapie von Lungenkrebs. Der Onkologe. 2021;27(11):1049-1057.
    https://doi.org/10.1007/s00761-021-01041-3
  • Presentations at scientific meetings/conferences

  • Schwarz S, Braitmaier M, Didelez V, Haug U. 13-year colorectal cancer risk: Comparing persons with a low- vs. high-quality screening colonoscopy vs. no screening colonoscopy. 18. Jahrestagung der Deutschen Gesellschaft für Epidemiologie (DGEpi), 26.-28. September 2023, Würzburg.
  • Hornschuch M, Schwarz S, Haug U. Screen-detected vs. non-screen-detected colorectal cancer in Germany: A claims data analysis. 17. Jahrestagung der Deutschen Gesellschaft für Epidemiologie (DGEpi), 26.-29. September 2022, Greifswald.
  • Schwarz S, Hornschuch M, Pox C, Haug U. Polyp detection rate and cumulative incidence of post-colonoscopy colorectal cancer in Germany. 17. Jahrestagung der Deutschen Gesellschaft für Epidemiologie (DGEpi), 26.-29. September 2022, Greifswald.
  • Braitmaier M, Schwarz S, Kollhorst B, Didelez V, Haug U. Effectiveness of screening colonoscopy in reducing colorectal cancer incidence - Emulated target trials from German claims data. 42nd Conference of the International Society for Clinical Biostatistics (ISCB), 18-22 July 2021, online presentation.
  • Hornschuch M, Schwarz S, Haug U. 10-year prevalence of diagnostic and screening colonoscopy use in Germany: A claims data analysis. Viszeralmedizin, 13.-18. September 2021, Leipzig. (Abstract publiziert in: Zeitschrift für Gastroenterologie. 2021;59:e182)
  • Schwarz S, Haug U. Colorectal cancer incidence within 10 years among one million persons undergoing screening colonoscopy: A claims data analysis. United European Gastroenterology (UEG) Week, 3-5 October 2021, online presentation. (Abstract published in: United European Gastroenterology Journal. 2021;9(S8):126)
  • Haug U, Schwarz S. Studies on the effect of drugs on colorectal cancer incidence: Considerable risk of misleading results. 36th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), 16-17 September 2020, online presentation. (Abstract published in: Pharmacoepidemiology & Drug Safety. 2020;29(S3):4673)
  • Posters at scientific meetings/conferences

  • Braitmaier M, Schwarz S, Didelez V, Haug U. Time-zero violations cause bias in observational studies on screening colonoscopy. Conference of the International Cancer Screening Network (ISCN), 21-23 June 2023, Turin, Italy.
  • Braitmaier M, Schwarz S, Didelez V, Haug U. Time-zero violations cause bias in observational studies on screening colonoscopy. United European Gastroenterology Week (UEG), 14-17 October 2023, Copenhagen, Denmark.
  • Hornschuch M, Schwarz S, Haug U. Screen-detected vs. non-screen-detected colorectal cancer in Germany: A claims data analysis. Conference of the International Cancer Screening Network (ISCN), 21-23 June 2023, Turin, Italy.
  • Hornschuch M, Schwarz S, Haug U. Utilization of colorectal cancer screening and diagnostic colonoscopy in Germany: A longitudinal analysis. Conference of the International Cancer Screening Network (ISCN), 21-23 June 2023, Turin, Italy.
  • Hornschuch M, Schwarz S, Haug U. Utilization of examinations for screening or diagnosis of colorectal cancer in Germany: A longitudinal analysis. United European Gastroenterology (UEG) Week, 14-17 October 2023, Copenhagen, Denmark.
  • Schwarz S, Braitmaier M, Didelez V, Haug U. 13-year colorectal cancer risk: Comparing persons with a low- vs. high-quality screening colonoscopy vs. no screening colonoscopy. Conference of the International Cancer Screening Network (ISCN), 21-23 June 2023, Turin, Italy.
  • Schwarz S, Braitmaier M, Didelez V, Haug U. 13-year colorectal cancer risk: Comparing persons with a low- vs. high-quality screening colonoscopy vs. no screening colonoscopy. United European Gastroenterology (UEG) Week, 14-17 October 2023, Copenhagen, Denmark.
  • Hornschuch M, Schwarz S, Haug U. Screen-detected vs. non-screen-detected colorectal cancer in Germany: A claims data analysis. 3rd International Conference on Cancer Prevention, 26-27 October 2022, Heidelberg.
  • Hornschuch M, Schwarz S, Haug U. Screen-detected vs. non-screen-detected colorectal cancer in Germany: A claims data analysis. United European Gastroenterology Week (UEG), 8-11 October 2022, Vienna, Austria.
  • Reilev M, Bjødstrup Jensen P, Støvring H, Skov Ranch L, Gini R, Bartolini C, Trifirò G, Kirchmayer U, Cesare Rosa A, Belleudi V, Haug U, Schwarz S, Schäfer W, Herings R, Smits E, Overbeek J, Holthuis E, Furu K, Gembert K, Hägg D, Tari M, Lentile V, Ingrasciotta Y, Egenberg A, Hallas J, on behalf of the BRAHMS study group. BRodalumab Assessment of Hazards: A Multinational Safety (BRAHMS) study of a biological anti-psoriatic drug across six European countries. 38th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), 24-28 August 2022, Copenhagen, Denmark. (Abstract published in: Pharmacoepidemiology and Drug Safety. 2022;31(Suppl. 2):487)
  • Schwarz S, Hornschuch M, Pox C, Haug U. Polyp detection rate and cumulative incidence of post-colonoscopy colorectal cancer in Germany. United European Gastroenterology Week (UEG), 8-11 October 2022, Vienna, Austria.
  • Schwarz S, Hornschuch M, Pox C, Haug U. Polyp detection rate and cumulative incidence of post-colonoscopy colorectal cancer in Germany. 3rd International Conference on Cancer Prevention, 26-27 October 2022, Heidelberg.
  • Hornschuch M, Schwarz S, Haug U. 10-year prevalence of diagnostic and screening colonoscopy use in Germany: A claims data analysis. 16. Jahrestagung der Deutschen Gesellschaft für Epidemiologie (DGEpi), 20.-22. September 2021, Online-Poster. (Abstract publiziert in: United European Gastroenterol Journal. 2021;9(S8):825)
  • Hornschuch M, Schwarz S, Haug U. 10-year prevalence of diagnostic and screening colonoscopy use in Germany: A claims data analysis. United European Gastroenterology (UEG) Week, 3-5 October 2021, online poster.
  • Schwarz S, Haug U. Colorectal cancer incidence within 10 years among one million persons undergoing screening colonoscopy: A claims data analysis. 16. Jahrestagung der Deutschen Gesellschaft für Epidemiologie (DGEpi), 20.-22. September 2021, Online-Poster.
  • Schwarz S, Haug U. Utilization of repeat colonoscopies and polypectomies in Germany within 10 years: A claims data analysis based on more than 2 million index colonoscopies. 34. Deutscher Krebskongress, 19.-22. Februar 2020, Berlin.
  • Schwarz S, Oppelt KA, Haug U. Using German claims data to characterize real-world treatment patterns in cancer patients - The example of crizotinib. 34. Deutscher Krebskongress, 19.-22. Februar 2020, Berlin.
  • Schwarz S, Oppelt KA, Haug U. The potential of German claims data to characterize real-world treatment patterns in cancer patients - The example of crizotinib. 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), 24-28 August 2019, Philadelphia, USA. (Abstract published in: Pharmacoepidemiology & Drug Safety. 2019;28(S2):221)

For further publications please follow this link:

  • Travel Grant
    United European Gastroenterology (ueg) Week (2023)
    Reisekostenfinanzierung von Jungwissenschaftlern mit "best submitted clinical science abstracts"

The responsibility for the content of this page lies with Sarina Schwarz.

Sarina Schwarz

Contact

Phone:
+49 (0)421 218-56-884